Docoh
Loading...

NTUS Natus Medical

Natus Medical Incorporated is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.

Company profile

Ticker
NTUS
Exchange
Website
CEO
Jonathan Kennedy
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
770154833

NTUS stock data

(
)

Calendar

7 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 80.55M 80.55M 80.55M 80.55M 80.55M 80.55M
Cash burn (monthly) 511K 2.21M (positive/no burn) 1.04M (positive/no burn) (positive/no burn)
Cash used (since last report) 1.42M 6.15M n/a 2.89M n/a n/a
Cash remaining 79.13M 74.4M n/a 77.66M n/a n/a
Runway (months of cash) 154.8 33.7 n/a 74.9 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Jun 21 Daskal Ilan Common Stock, $0.001 par value per share Grant Aquire A No No 28.77 5,214 150.01K 13,862
17 Jun 21 Schroeder Alice D. Common Stock, $0.001 par value per share Grant Aquire A No No 28.77 5,214 150.01K 17,331
17 Jun 21 Heine Lisa Wipperman Common Stock, $0.001 par value per share Grant Aquire A No No 28.77 5,214 150.01K 21,212
17 Jun 21 Levine Joshua Common Stock, $0.001 par value per share Grant Aquire A No No 28.77 5,214 150.01K 32,312
17 Jun 21 Paul Barbara R Common Stock, $0.001 par value per share Grant Aquire A No No 28.77 5,214 150.01K 29,772

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 151 162 -6.8%
Opened positions 16 23 -30.4%
Closed positions 27 18 +50.0%
Increased positions 48 51 -5.9%
Reduced positions 64 59 +8.5%
13F shares
Current Prev Q Change
Total value 1.15B 633.06M +81.5%
Total shares 31.51M 31.54M -0.1%
Total puts 54.2K 89.5K -39.4%
Total calls 12.9K 17.8K -27.5%
Total put/call ratio 4.2 5.0 -16.4%
Largest owners
Shares Value Change
BLK Blackrock 6.49M $166.21M +13.3%
Vanguard 2.88M $73.73M +3.2%
Victory Capital Management 2M $51.14M -1.7%
WFC Wells Fargo & Co. 1.49M $38.03M +16.4%
STT State Street 1.34M $34.29M +1.7%
Nuveen Asset Management 1.2M $30.75M +5.7%
Dimensional Fund Advisors 1.2M $30.76M -2.9%
JHG Janus Henderson 1.14M $29.18M -0.0%
Wellington Management 829.35K $21.24M -7.2%
AMP Ameriprise Financial 722.33K $18.5M +178.8%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 6.49M +760.43K +13.3%
AMP Ameriprise Financial 722.33K +463.2K +178.8%
Norges Bank 0 -426.24K EXIT
Renaissance Technologies 592.97K -232.8K -28.2%
WFC Wells Fargo & Co. 1.49M +209.49K +16.4%
Liontrust Investment Partners 0 -178.94K EXIT
Millennium Management 58.84K -162.08K -73.4%
MS Morgan Stanley 303.42K +159.42K +110.7%
GS Goldman Sachs 576.51K -122.41K -17.5%
IVZ Invesco 625.05K -108.9K -14.8%

Financial report summary

?
Risks
  • Our business has been and may continue to be negatively affected by the ongoing COVID-19 pandemic and any future outbreaks of disease.
  • Because we rely on distributors or sub-distributors to sell our products in most of our markets outside of the United States, our revenue could decline if our existing distributors reduce the volume of purchases from us, or if our relationship with any of these distributors is terminated.
  • If we lose our relationship with any supplier of key product components or our relationship with a supplier deteriorates or key components are not available in sufficient quantities, our manufacturing could be delayed and our business could suffer.
  • We have substantial international operations which are subject to numerous risks; if our international operations are not successful, our business will be adversely affected.
  • We previously identified a material weakness in our internal control over financial reporting in recent periods, and if we fail to maintain proper and effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act in the future, the accuracy and timeliness of our financial reporting may be adversely affected.
  • The United Kingdom's withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business and operations.
  • Our operating results may suffer because of our exposure to foreign currency exchange rate fluctuations.
  • The interest rates on our revolving credit facility are priced using a spread over LIBOR.
  • Future changes in technology or market conditions could result in adjustments to our recorded asset balance for intangible assets, including goodwill, resulting in additional charges that could significantly impact our operating results.
  • We depend upon key employees in a competitive market for skilled personnel, and, without additional employees, we cannot grow or maintain profitability.
  • We have experienced seasonality in the sale of our products.
  • We make regular changes to our information systems that could disrupt our business and our financial results.
  • U.S. tax reform legislation could materially affect our business and financial condition.
  • Demand for some of our products depends on the capital spending policies of our customers, and changes in these policies could harm our business.
  • Our operating results may decline if we do not succeed in developing, acquiring, and marketing additional products or improving our existing products.
  • Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
  • At previous points in our past, our growth has depended substantially on the completion of acquisitions and we may not be able to complete or successfully capitalize on acquisitions of the same nature or relative size in the future to support a similar level of growth.
  • If we fail in our efforts to educate clinicians, government agency personnel, and third-party payors about the effectiveness of our products, we may not achieve future sales growth.
  • Sales to members under group purchasing agreements and sales to high volume purchasers may reduce our average selling prices, which could reduce our operating margins.
  • Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
  • Our markets are very competitive and in the United States we sell certain of our products in a mature market.
  • If healthcare providers are not adequately reimbursed for procedures conducted with our devices or supplies, or if reimbursement policies change adversely, we may not be successful marketing and selling our products or technologies.
  • Our ability to market and sell products depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations. Our failure to obtain or maintain regulatory approvals and compliance could negatively affect our business.
  • Our business would be harmed if the FDA determines that we have failed to comply with applicable regulations governing the manufacture of our products and/or we do not pass an inspection.
  • If we deliver products with defects, we may incur costs to repair and, possibly, recall that product and market acceptance of our products may decrease.
  • Our business may suffer if we are required to revise our labeling or promotional materials, or if the FDA takes an enforcement action against us for off-label uses.
  • We are subject to data privacy laws and our failure to comply with them may require us to make significant changes to our products or incur penalties or other liabilities.
  • An interruption in or breach of security of our information or manufacturing systems, including the occurrence of a cyber-incident or a vulnerability in our cybersecurity, or disclosure of private patient health information, may result in a loss of business or damage to our reputation.
  • Regulations related to “conflict minerals” may force us to incur additional expenses, may result in damage to our business reputation and may adversely impact our ability to conduct our business.
  • If guidelines mandating universal newborn hearing screening do not continue to develop in foreign countries and governments do not mandate testing of all newborns as we anticipate, or if those guidelines have a long phase-in period, our sales of newborn hearing screening products may not achieve the revenue growth we have achieved in the past.
  • If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
  • We may not be able to preserve the value of our intellectual property because we may not be able to protect access to it or we may lose our intellectual property rights due to expiration of our licenses or patents.
  • Our operating results would suffer if we were subject to a protracted infringement claim.
  • We license intellectual property rights from third parties and would be adversely affected if our licensors do not appropriately defend their proprietary rights or if we breach any of the agreements under which we license commercialization rights to products or technology from others.
  • Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages, and an increase in our insurance rates.
Management Discussion
  • Our business and operating results are driven in part by worldwide economic conditions. Our revenue is significantly dependent on both capital spending by hospitals in the United States and healthcare spending by ministries of health outside the United States.
  • We experienced an increase in demand, particularly in Asia Pacific and Europe, during the first quarter compared to the same period in the prior year as recovery from the COVID-19 pandemic continues. Our consolidated revenue for the first quarter ended March 31, 2021 was $114.9 million compared to $109.4 million in the first quarter of the previous year, an increase of $5.5 million.
  • Our net income was $2.4 million or $0.07 per diluted share in the three months ended March 31, 2021, compared with net loss of $3.6 million or $0.11 per share in the same period in 2020. The increase in net income was the result of higher revenue due to the recovery from impact of COVID-19, in particular in international markets for Neuro products, and lower expenses compared to the prior year, driven by the timing of engineering project spend and the benefit of COVID-19 payroll relief received in Canada.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: assurance, assured, established, fraud, inherent, intraoperative, Mach, method, mix, onset, outlook, Pacific, Phototherapy, seek, set, slight, slightly, speak, strength, Subsidy, Wage
Removed: abroad, accrual, accuracy, achievement, Additionally, ambulatory, anticipate, arrangement, ASU, audit, August, award, bad, begun, book, build, cancelling, capitalize, CEO, CFO, checklist, committee, comparability, conclusion, conduct, confirming, coordinated, curfew, cyber, defense, deferring, deficiency, direct, disease, disrupt, disrupted, document, drop, EEG, efficiency, elimination, enable, enhanced, error, existed, expectation, expenditure, experiencing, Finally, flag, formalize, format, franchise, free, generating, GND, goal, grant, heightened, heightening, identification, identify, immaterial, impacted, impair, implement, improvement, improving, indirect, infection, insufficient, involve, isolation, issued, January, June, large, local, long, manual, materiality, Medix, methodology, misstatement, monitor, Neurocom, operator, option, outcome, oversight, partially, paying, payout, pertinent, pool, President, previously, privacy, productivity, professional, prolonged, proper, properly, PSU, quarantine, relevant, remediate, remediated, remediating, remote, remotely, removal, repeat, requisite, responsible, resulted, resume, reviewer, security, senior, separate, signoff, simplification, Simplifying, Specifically, state, substantive, successful, supporting, targeted, temporarily, temporary, tender, terminology, Topic, Trump, turn, understood, verify, vest, vested, widespread, worker, workforce

Patents

GRANT
Utility
Audiologic test probe with locking mechanism, and a component for the test probe
23 Nov 20
An audiologic test probe with locking mechanism, and a component for the test probe is disclosed.
APP
Utility
Real-time Removal of Ir Led Reflections from an Image
29 Jan 20
A system for the real-time removal of reflections from an image including a head wearable device, a first illuminator, a second illuminator, at least one camera and a reflection removal processor.
APP
Utility
Vestibular Testing Apparatus
15 Jan 20
A system for detecting and recording head orientations of a person includes: a first sensor device capable of providing sensor data regarding a head orientation of a person in a three-dimensional space; a data acquisition system configured for storing and outputting the sensor data from the first sensor device; and a processor configured for processing the sensor data from the data acquisition system, outputting a first signal representing the head orientation, and generating an image for presentation by a graphical display; wherein the image comprises: a first reference indicator; an orientation indicator, wherein a position of the orientation indicator in the image is determined based on the first signal from the processor, and a feedback indicator when a first condition is met.
GRANT
Utility
Audiologic test apparatus and method
14 Oct 19
An audiologic test apparatus includes: a pump device configured to apply a first pressure to the ear canal; and a processing module for communicatively coupling to the pump device and to a signal generator, wherein the processing module is configured to obtain first acoustic parameter values indicative of an acoustic parameter at the first pressure based on a first broadband signal generated using the signal generator; wherein the pump device is configured to change the first pressure to a changed pressure, and wherein the pump device is also configured to apply a second pressure to the ear canal; and wherein the processing module is also configured to obtain second acoustic parameter values indicative of the acoustic parameter at the second pressure based on a second broadband signal generated using the signal generator, and determine a middle ear resonance frequency based on the first and second acoustic parameter values.
GRANT
Utility
Vestibular testing apparatus
30 Sep 19
A system for detecting and recording head orientations of a person includes: a first sensor device capable of providing sensor data regarding a head orientation of a person in a three-dimensional space; a medical data acquisition system configured for storing and outputting the sensor data from the first sensor device; and a processor configured for processing the sensor data from the medical data acquisition system, outputting a first signal representing the head orientation, and generating an image for presentation by a graphical display; wherein the image comprises: a first reference indicator; an orientation indicator, wherein a position of the orientation indicator in the image is determined based on the first signal from the processor, and a feedback indicator when a first condition is met.